Scientific Sessions 2024  /  Translational Discovery in Thrombosis and Anti-thrombotic Therapeutics  /  New mechanisms for antiplatelet therapies
Logo

American Heart Association

  145
  0

Final ID:

New mechanisms for antiplatelet therapies

  • Holinstat, Michael  ( University of Michigan , Ann Arbor , Michigan , United States )
    • Author Disclosures:
    Michael Holinstat: DO have relevant financial relationships ; Consultant:Veralox Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Cereno Scientific:Past (completed) ; Royalties/Patent Beneficiary:Cereno Scientific:Active (exists now) ; Consultant:Cereno Scientific:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Translational Discovery in Thrombosis and Anti-thrombotic Therapeutics

Saturday, 11/16/2024 , 03:15PM - 04:30PM

Abstract Oral Session

More abstracts on this topic:
Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Transporters 1 and 2, Elicits Cardioprotective Effects Through Attenuation of Platelet Activation and Thrombosis

Stanger Livia, Rickenberg Andrew, Yalavarthi Pooja, Flores Mariane, Yamaguchi Adriana, Pitt Bertram, Holinstat Michael

Building Nucleic Acid-Based Hirudins：Potent, Selective, and Reversible Protease Inhibitors

Yu Haixiang, Yan Amy, Pitoc George, Garber Susannah, Clancy Jeffrey, Sullenger Bruce

More abstracts from these authors:
Sustained Anti-Thrombotic Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic Potential

Stanger Livia, Flores Mariane, Yalavarthi Pooja, Dahlof Bjorn, Holinstat Michael

Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Transporters 1 and 2, Elicits Cardioprotective Effects Through Attenuation of Platelet Activation and Thrombosis

Stanger Livia, Rickenberg Andrew, Yalavarthi Pooja, Flores Mariane, Yamaguchi Adriana, Pitt Bertram, Holinstat Michael

You have to be authorized to contact abstract author. Please, Login
Not Available